GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Isofol Medical AB (FRA:5IU) » Definitions » EV-to-EBITDA

Isofol Medical AB (FRA:5IU) EV-to-EBITDA : 1.02 (As of May. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Isofol Medical AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Isofol Medical AB's enterprise value is €-3.25 Mil. Isofol Medical AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.18 Mil. Therefore, Isofol Medical AB's EV-to-EBITDA for today is 1.02.

The historical rank and industry rank for Isofol Medical AB's EV-to-EBITDA or its related term are showing as below:

FRA:5IU' s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.94   Med: -3.73   Max: 2.47
Current: 1.04

During the past 9 years, the highest EV-to-EBITDA of Isofol Medical AB was 2.47. The lowest was -12.94. And the median was -3.73.

FRA:5IU's EV-to-EBITDA is ranked better than
72.39% of 460 companies
in the Biotechnology industry
Industry Median: 9.53 vs FRA:5IU: 1.04

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Isofol Medical AB's stock price is €0.0469. Isofol Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.020. Therefore, Isofol Medical AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Isofol Medical AB EV-to-EBITDA Historical Data

The historical data trend for Isofol Medical AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isofol Medical AB EV-to-EBITDA Chart

Isofol Medical AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -3.28 -11.87 -5.62 0.42 0.55

Isofol Medical AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.52 0.95 0.14 0.55

Competitive Comparison of Isofol Medical AB's EV-to-EBITDA

For the Biotechnology subindustry, Isofol Medical AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Isofol Medical AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Isofol Medical AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Isofol Medical AB's EV-to-EBITDA falls into.



Isofol Medical AB EV-to-EBITDA Calculation

Isofol Medical AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-3.245/-3.181
=1.02

Isofol Medical AB's current Enterprise Value is €-3.25 Mil.
Isofol Medical AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Isofol Medical AB  (FRA:5IU) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Isofol Medical AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0469/-0.020
=At Loss

Isofol Medical AB's share price for today is €0.0469.
Isofol Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.020.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Isofol Medical AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Isofol Medical AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Isofol Medical AB (FRA:5IU) Business Description

Traded in Other Exchanges
Address
Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.

Isofol Medical AB (FRA:5IU) Headlines

No Headlines